Nymox Announces Date for Fexapotide Filing NEWS RELEASE HASBROUCK HEIGHTS, NJ (May 6, 2021) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or before 15 September 2021. CEO Dr Paul Averback said, "The Company will file on or before September 15. We hope but cannot be certain that the date may be before September. Company management will communicate updates where appropriate."